Exposure to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors and the association with neurocognitive side effects: a meta-analysis and meta-regression
Event:
ESC Congress 2020
Topic:
Lipid-Lowering Agents
Session:
Pharmacology and Pharmacotherapy ePosters
